Filing Details

Accession Number:
0000899243-20-015623
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-08 16:17:07
Reporting Period:
2020-06-04
Accepted Time:
2020-06-08 16:17:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1680581 Fulcrum Therapeutics Inc. FULC Pharmaceutical Preparations (2834) 474839948
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1778713 Diego Cadavid C/O Fulcrum Therapeutics, Inc.
26 Landsdowne Street
Cambridge MA 02139
Svp Clinical Development No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-06-04 226 $4.83 67,011 No 4 M Direct
Common Stock Disposition 2020-06-04 226 $20.05 66,785 No 4 S Direct
Common Stock Acquisiton 2020-06-05 451 $4.83 67,236 No 4 M Direct
Common Stock Disposition 2020-06-05 451 $20.18 66,785 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-06-04 226 $0.00 226 $4.83
Common Stock Stock Option (right to buy) Disposition 2020-06-05 451 $0.00 451 $4.83
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
14,588 2028-07-10 No 4 M Direct
14,137 2028-07-10 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $20.31, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
  4. The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022.